264260-06-2

Basic information

• Product Name: 4-hydroxy-6-nitroquinolin-2(1H)-one
• Synonyms: 4-hydroxy-6-nitroquinolin-2(1H)-one;4-hydroxy-6-nitro-2(1H)-Quinolinone
• CAS NO: 264260-06-2
• Molecular Formula: C₉H₆N₂O₄
• Molecular Weight: 206.16
• Mol File: 264260-06-2.mol

Chemical Properties

• Boiling Point: 501.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.599±0.06 g/cm3(Predicted)
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: 4-hydroxy-6-nitroquinolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxy-6-nitroquinolin-2(1H)-one(264260-06-2)
• EPA Substance Registry System: 4-hydroxy-6-nitroquinolin-2(1H)-one(264260-06-2)

Safety Data

• Hazardous Substances Data: 264260-06-2(Hazardous Substances Data)

Upstream product

• 5502-62-5 N-(4-nitro-phenyl)-malonamic acid 
• 5409-45-0 2-acetylamino-5-nitrobenzoic acid methyl ester 
• 70254-43-2 4-Hydroxy-2-quinolone 
• 100-01-6 4-nitro-aniline 
• 105-53-3 diethyl malonate 
• 125600-42-2 2-amino-5-nitrophenylacetylene 
• 124-38-9 carbon dioxide 
• 70254-44-3 2,4-dihydroxyquinoline 
• 3816-62-4 5-nitroanthranilic acid methyl ester 
• 10390-08-6 ethyl 3-((4-nitrophenyl)amino)-3-oxopropanoate 

Downstream Products

• 437708-86-6 2,4-dibromo-6-nitroquinoline 
• 408523-59-1 2,4-dichloro-6-nitroquinoline 
• 5045-89-6 6-amino-4-hydroxyquinolin-2(1H)-one 
• 437708-76-4 4-chloro-6-nitro-2-piperazin-1-yl-quinoline 
• 143954-73-8 4-Bromo-6-nitro-2-piperazin-1-yl-quinoline 

Relevant articles and documents

The discovery of quinoline derivatives, as NF-κB inducing kinase (NIK) inhibitors with anti-inflammatory effects in vitro, low toxicities against T cell growth

NIK is a critical regulatory protein of the non-classical NF-kB pathway, and its dysregulated activation has been proved to be one of the pathogenic factors in a variety of autoimmune diseases and inflammatory diseases. Nevertheless, its corresponding dev

Method for preparing 4-hydroxyquinolin-2(1H)-one compound

The invention discloses a method for preparing a 4-hydroxyquinolin-2(1H)-one compound, which comprises the following steps of: reacting 2-ethynylaniline as shown in a formula (1) and carbon dioxide which are used as raw materials in an ionic liquid in the presence of a silver salt catalyst to obtain the 4-hydroxyquinoline-2 (1H)-one compound as shown in a formula (II). The reaction equation is shown in the specification. When the method disclosed by the invention is applied to the reaction for preparing the 4-hydroxyquinolin-2(1H)-one compound, the reaction conditions are relatively mild, the dosage of the silver salt catalyst is small, the separation and purification process of the product is relatively simple, the product yield is high, and the application range of a substrate is wide.

One-step Synthesis of 3-Unsubstituted 4-Hydroxy-2(1H)-Quinoline

3-Unsubstituted 4-hydroxy-2(1H)-quinolone (DHQ) derivatives were synthesized from aniline derivatives and diethyl malonate at low temperature using AlCl3 as catalyst and Eaton reagent as acidic environment. A reaction mechanism was proposed and elucidated. Different synthetic intermediates are specially prepared or purified and used to understand the reaction and validation mechanism.

Synthesis and structure elucidation of some new azo dye from hydroxyquinolin-2(1H)-one derivatives and their antimicrobial evaluation

The aim of the work is synthesis of some novel azo dye from 1,2-dihydro-4-hydroxy-2-oxoquinoline-6-sulfonic acid (3), 4-hydroxy-6-methoxyquinolin-2(1H)-one (4), and 4-hydroxy-6-nitroquinolin-2(1H)-one (5). The prepared compounds were screened for antibact

4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS

4-aryloxyquinolin-2(1H)-ones as mtor kinase and PI3 kinase inhibitors, for use as anti-cancer agents. Compounds of the formula I and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, R3, R4, R5, R6, and R7 are defined as set forth herein are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds of the invention and a pharmaceutically acceptable carrier, methods of making the compounds of the invention and methods of using the compounds for inhibiting mTOR and PI3 kinases and for treating cancers.

Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones

A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.

INHIBITORS OF FATTY ACID SYNTHASE (FAS)

The instant invention provides for compounds which comprise substituted 3-aryl-4-hydroxyquinolin-2(1H)-ones that inhibit FAS activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting FAS activity

QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS

The present invention is directed to certain quinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors

A series of 3-aryl-4-hydroxyquinolin-2(1H)-ones with fatty acid synthase inhibitory activity was prepared. Starting from a derivative with an IC50 = 1.4 μM, SAR studies led to compounds with more than 70-fold increase in potency (IC50/sub

Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-Substituted 6-nitroquipazines

Eleven 4-substituted derivatives of 6-nitroquipazine were synthesized and evaluated for their abilities to displace [3H]citalopram binding to the rat cortical synaptic membranes. Among them, 4-chloro-6-nitroquipazine was shown to possess the hi